Asberg A - Search Results

1

OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture.

Ulvestad M, Björquist P, Molden E, Asberg A, Andersson TB. Ulvestad M, et al. Among authors: asberg a. Biochem Pharmacol. 2011 Nov 1;82(9):1219-26. doi: 10.1016/j.bcp.2011.07.076. Epub 2011 Jul 20. Biochem Pharmacol. 2011. PMID: 21787759

2

Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients.

Asberg A, Christensen H, Hartmann A, Carlson E, Molden E, Berg KJ. Asberg A, et al. Eur J Clin Pharmacol. 1999 Jul;55(5):383-7. doi: 10.1007/s002280050644. Eur J Clin Pharmacol. 1999. PMID: 10456488

3

CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells.

Molden E, Asberg A, Christensen H. Molden E, et al. Among authors: asberg a. Eur J Clin Pharmacol. 2000 Nov;56(8):575-9. doi: 10.1007/s002280000182. Eur J Clin Pharmacol. 2000. PMID: 11151747

4

[Metabolic interactions with statins].

Molden E, Asberg A. Molden E, et al. Among authors: asberg a. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93. Tidsskr Nor Laegeforen. 2001. PMID: 11475198 Review. Norwegian.

5

Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4.

Molden E, Asberg A, Christensen H. Molden E, et al. Among authors: asberg a. Drug Metab Dispos. 2002 Jan;30(1):1-3. doi: 10.1124/dmd.30.1.1. Drug Metab Dispos. 2002. PMID: 11744603

6

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.

Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K. Hermann M, et al. Among authors: asberg a. Clin Pharmacol Ther. 2006 Jun;79(6):532-9. doi: 10.1016/j.clpt.2006.02.014. Clin Pharmacol Ther. 2006. PMID: 16765141

7

Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system.

Ulvestad M, Darnell M, Molden E, Ellis E, Åsberg A, Andersson TB. Ulvestad M, et al. Among authors: asberg a. J Pharmacol Exp Ther. 2012 Oct;343(1):145-56. doi: 10.1124/jpet.112.195750. Epub 2012 Jul 12. J Pharmacol Exp Ther. 2012. PMID: 22789711

8

Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.

Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, Hjelmesæth J, Andersson TB, Sandbu R, Christensen H. Ulvestad M, et al. Among authors: asberg a. Clin Pharmacol Ther. 2013 Mar;93(3):275-82. doi: 10.1038/clpt.2012.261. Epub 2012 Dec 27. Clin Pharmacol Ther. 2013. PMID: 23361102

9

Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Størset E, et al. Among authors: asberg a. Br J Clin Pharmacol. 2017 Jun;83(6):1350-1352. doi: 10.1111/bcp.13188. Epub 2016 Dec 22. Br J Clin Pharmacol. 2017. PMID: 28008657 Free PMC article. No abstract available.

10

The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Størset E, et al. Among authors: asberg a. Br J Clin Pharmacol. 2017 Jul;83(7):1457-1465. doi: 10.1111/bcp.13248. Epub 2017 Feb 27. Br J Clin Pharmacol. 2017. PMID: 28146606 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

420 results

Search Page

Filters